Bozic Carmen sold $888K of VRTX

Vertex Pharmaceuticals (VRTX) completed its largest acquisition, Crinetics, for $10B, gaining Palsonify and Atumelnant. Palsonify, for acromegaly, and Atumelnant, for CAH and Cushing's syndrome, could generate over $5B in peak revenue. Vertex aims to diversify beyond cystic fibrosis with these and other pipeline drugs.

Biotech stocks are rebounding due to record pharmaceutical M&A deals, with 37 acquisitions worth at least $1B each in 2026, totaling $216B. Key deals include Vertex (VRTX) acquiring Crinetics (CRNX) for $10B. Institutional investors are bullish, but retail sentiment is low. The Direxion Biotech Bull 3x Shares (LABU) fund has gained 52.5% YTD, despite its index being down last week.

BofA Securities reduced its price target for Vertex Pharmaceuticals (VRTX) to $667 from $672, maintaining a Buy rating. The company expects Q3 revenue of $2.42B for Trikafta, down 3% QoQ, and raised its 2026 revenue guidance to $13.1B-$13.2B. Vertex is a top pick for 2026, according to BofA, which is bullish on its cystic fibrosis franchise. Other analysts have also raised price targets following positive trial data for its kidney disease treatment, inaxaplin.

Vertex Pharmaceuticals (VRTX) presented new data on ALYFTREK at the North American Cystic Fibrosis Conference, showing recovery of pancreatic function in some children aged 2 to 5. The study found a mean increase of 110.2 µg/g in fecal elastase-1 levels, with 48.6% of children reaching pancreatic sufficiency. Vertex also shared additional abstracts on CFTR modulators. ALYFTREK is investigational for this age group.

Vertex Pharmaceuticals (VRTX) reported interim data showing 37.5% of young CF patients aged 2-5 recovered pancreatic function after ALYFTREK treatment. 50% of 66 children discontinued pancreatic enzyme therapy. Mean fecal elastase-1 levels increased by 110.2 μg/g. Data presented at the North American Cystic Fibrosis Conference. ALYFTREK is investigational for this age group.

Vertex Pharmaceuticals reported interim data suggesting ALYFTREK may restore pancreatic function in 2–5 year-olds with cystic fibrosis, potentially allowing discontinuation of pancreatic enzyme replacement therapy. The use of ALYFTREK in this age group is still investigational, according to the company.